Neurimmune today announced that long-term safety and efficacy data from the open-label extension of a Phase I trial related to ALXN2220 (formerly NI006) for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) will be presented in London at the ESC Congress 2024, a scientific congress of the European Society of Cardiology (ESC), on September 1, 17:48 UK time. Professor Peter van der Meer from the University Medical Centre Groningen, Netherlands, will present during the session for Advances in Amyloidosis.
Presentation Details:
Title: Long-term safety and efficacy of antibody ALXN2220 for depletion of cardiac amyloid transthyretin: Results of treatment beyond 12 months in the open-label extension of study NI006-101
Presenter: Peter van der Meer, MD, PhD, Cardiologist, University Medical Center Groningen (UMCG)
Session: Advances in Amyloidosis
Date: September 1, 2024
Time: 17:48 UK time
Location: Science Box 1
Amyloid transthyretin cardiomyopathy (ATTR-CM) is increasingly recognized as a treatable cause of heart failure. Progressive ATTR amyloid depositions characterize the disease, leading to progressive heart failure and a high rate of fatality if left untreated. Despite recent advances in slowing disease progression, there is no treatment available to deplete cardiac ATTR amyloid and revert cardiac dysfunction.
ALXN2220 is an investigational human monoclonal antibody designed to deplete amyloid deposits in ATTR-CM as add-on to standard of care.1,2 At the ESC Congress 2024, Neurimmune, Alexion, AstraZeneca Rare Disease and the clinical investigators will present new long-term safety, tolerability and efficacy data of ALXN2220 treatment beyond 12 months which was studied in a prolonged Open-Label Extension of the NI006-101 trial.
Prof. Christoph Hock, Chief Medical Officer of Neurimmune, said: “The depletion of the cardiac ATTR amyloid deposits is a rational therapeutic target to revert disease pathology and restore organ function. Our data at ESC Congress 2024 underscores the commitment of Neurimmune and our partner Alexion to evaluate the safety and efficacy of longer-term ALXN2220 treatment to develop a best-in-class option for patients with ATTR-CM and to increase our understanding of the mechanisms underlying amyloid depletion.”
In 2022, Neurimmune entered into an exclusive global collaboration and license agreement with Alexion, AstraZeneca Rare Disease, for ALXN2220. Neurimmune is responsible for completion of the Phase 1b clinical study on behalf of Alexion, with Alexion incurring certain trial costs. Aside from the Phase 1b trial, Alexion is responsible for further clinical development, manufacturing, and commercialization as ALXN2220. In 2024, Alexion initiated the Phase 3 DepleTTR-CM clinical study to assess the efficacy and safety of ALXN2220 for the treatment of ATTR-CM.
1Garcia-Pavia et al., N Engl J Med 2023; 389(3):239.
2Michalon et al., Nat Commun 2021; 12(1):3142.
About Neurimmune
Neurimmune is a biopharmaceutical company translating human immune memory into antibody therapeutics. Neurimmune develops drug candidates for CNS and related protein aggregation diseases including Alzheimer’s disease, amyotrophic lateral sclerosis, frontotemporal dementia and ATTR cardiomyopathy. With its Reverse Translational MedicineTM technology, Neurimmune discovered the brain amyloid depleter NI101SQ for Alzheimer’s disease, anti-SOD1 antibody AP-101 for ALS and the anti-ATTR antibody ALXN2220 (formerly NI006) for ATTR cardiomyopathy, programs being currently evaluated in clinical trials.
Contact for Media
John Capodanno (US)
john.capodanno@dentonsglobaladvisors.com
Martin Meier-Pfister (Switzerland)
media@neurimmune.com
